
Eytan M. Stein, MD
Hematologic Oncologist
Titles
Chief, Leukemia Service; Director, Program for Drug Development in Leukemia, Division of Hematologic Malignancies
Clinical Expertise
Acute and Chronic Leukemias; Myelodysplastic Syndrome; Myeloproliferative Neoplasms; Development of Novel Therapies for AML
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Stein accepts the following list of insurance providers. Select your insurance provider to see more details.
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO, DSN
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO EPO
Payor Type: Commercial
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): Federal Government
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP
Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): TBD
Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO
Payor Type: Commercial
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Contact and Location
- 646-608-3749 Office Phone
- Speaks English and Hebrew

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
See all locationsAbout Me
Education
MD, Northwestern University Medical School
Residencies
Northwestern Memorial Hospital
Fellowships
Memorial Sloan Kettering Cancer Center
Board Certifications
Internal Medicine; Medical Oncology; Hematology
I am a hematology-oncology physician who specializes in caring for people with acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms. I am dedicated to providing my patients with the best care tailored to their unique situation. To do this, we work together to develop a personalized treatment plan that takes into account their needs as well as their family’s. I am also an active clinical researcher who develops new and innovative approaches to treating acute myeloid leukemia (AML).
Read more
I am the principal investigator on a wide variety of clinical trials for people with AML. I am working to develop new therapies — such as small molecule inhibitors — that can more precisely and effectively target AML. My goal as a doctor and researcher is to help people with AML and other blood cancers have the best possible outcomes.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
See all Leukemia Service doctors
Clinical Trials
- Clinical Trials Investigated by Dr. Stein
- A Phase I Study of BTX-1188 in People with Acute Myeloid Leukemia
- A Phase I Study of CB-5339 for Recurrent or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndromes
- A Phase I Study of FHD-286 in People with Recurrent or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndromes
- A Phase I Study of LY3410738 in Patients with Advanced Blood Cancers with IDH1 or IDH2 Mutations
Read more
- A Phase I/II Study of SNDX-5613 in People with Recurrent or Persistent Acute Leukemia
- A Phase IB/II Study of Lanraplenib in Combination with Gilteritinib in People with FLT3-Mutated Recurrent or Persistent Acute Myeloid Leukemia
- A Phase II Study of BST-236 in People with Acute Myeloid Leukemia or Myelodysplastic Syndrome
- A Study of Enasidenib in People with Unexplained Low Blood Cell Counts
- A Study of Tamibarotene with Venetoclax and Azacitidine in People with Previously Untreated Acute Myeloid Leukemia with Certain Genetic Changes
- Clinical Trials Co-Investigated by Dr. Stein
- A Phase 1 Study of PRT1419 in People with Recurrent or Persistent Blood Cancers
- A Phase 1/2 Study of IMGN632 in People with Blastic Plasmacytoid Dendritic Cell Neoplasm
- A Phase 2 Study of AG-946 in People with Anemia Due to Myelodysplastic Syndromes
- A Phase I Study of CG-806 in People with Acute Myeloid Leukemia
- A Phase I Study of SNDX-5613 with Chemotherapy for People with Leukemia
- A Phase I Study of ZN-c3 and ZN-d5 in People with Recurrent or Persistent Acute Myeloid Leukemia
- A Phase III Study of Crenolanib or Midostaurin after Induction and Consolidation Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Stein’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Eytan M. Stein discloses the following relationships and financial interests:
-
AbbVie
Provision of Services -
Agios Pharmaceuticals
Provision of Services -
Auron Therapeutics, Inc.
Ownership / Equity Interests -
Bristol-Myers Squibb
Provision of Services -
CTI BioPharma Corp.
Provision of Services -
Calithera
Provision of Services -
Celgene
Provision of Services -
Epizyme
Provision of Services -
Genentech
Provision of Services -
Genesis Therapeutics
Provision of Services -
Gilead Pharmaceutical
Provision of Services
-
Janssen Pharmaceuticals, Inc.
Provision of Services -
Jazz Pharmaceuticals
Provision of Services -
Kronos Bio, Inc
Provision of Services -
Kura Oncology
Provision of Services -
Neoleukin Therapeutics, Inc.
Provision of Services -
Novartis Pharmaceuticals Corporation
Provision of Services -
PinotBio, Inc.
Provision of Services -
Servier
Provision of Services -
Syndax
Provision of Services -
Takeda Millennium
Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].